|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-7-8
|
|
pubmed:abstractText |
The release of brain natriuretic peptide (BNP) is increased in heart failure (HF). The plasma concentrations of BNP and N terminal pro-BNP (NT-proBNP) fall after effective pharmacologic treatment of HF, which suggests that measurements of plasma BNP may be helpful in evaluating therapy. Despite the initial reports that suggested a positive effect of levosimendan on short- and long-term survival in patients with severe HF, the results of the recently presented large-scale clinical trials provided rather controversial results. Further clinical studies are needed to end the confusion regarding the effects of levosimendan on prognosis in patients with decompansated HF.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1874-1754
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
128
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
97-9; authr reply 100-2
|
|
pubmed:meshHeading |
pubmed-meshheading:18501448-Cardiotonic Agents,
pubmed-meshheading:18501448-Dobutamine,
pubmed-meshheading:18501448-Heart Failure,
pubmed-meshheading:18501448-Humans,
pubmed-meshheading:18501448-Hydrazones,
pubmed-meshheading:18501448-Infusions, Intravenous,
pubmed-meshheading:18501448-Natriuretic Peptide, Brain,
pubmed-meshheading:18501448-Predictive Value of Tests,
pubmed-meshheading:18501448-Prognosis,
pubmed-meshheading:18501448-Pyridazines,
pubmed-meshheading:18501448-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
|
|
pubmed:publicationType |
Letter,
Comment
|
